Clinical trial
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2…
NCT00491725 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00491725 |
|---|---|
| Title | Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs |
| Official title | A Multi-centre, Single Armed, Open Labelled Trial to Study the Efficacy and Safety Profile of Repaglinide & Metformin Combination Therapy in Chinese Type 2 Diabetics |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | repaglinide, metformin |
| Enrollment | 187 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Jun 26, 2007 |
| Last update posted | Mar 3, 2016 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: